Effect of raloxifene and low-dose percutaneous 17β-estradiol on menopause symptoms and endometrium-A randomized controlled trial

Maturitas

Volumn 62, Issue 1, 2009, Pages 81-84

  Valiati, Beatriz ^a   Capp, Edison ^a,b   Edelweiss, Maria Isabel ^a,b   de Freitas, Fernando Monteiro ^a,b   Wender, Maria Celeste Osório ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Endometrium; Estradiol; Hot flushes; Raloxifene

Indexed keywords

ESTRADIOL; PLACEBO; RALOXIFENE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; FEMALE; HOT FLUSH; HUMAN; HYSTEROSCOPY; KUPPERMAN INDEX; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

ADMINISTRATION, CUTANEOUS; AGED; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; ESTROGENS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PATIENT SATISFACTION; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 58549116682     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2008.10.013     Document Type: Article

References (23)

1. Waetjen L.E., Brown J.S., Vittinghoff E., et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol 106 (2005) 946-952
2. Komulainen M., Kroger H., Tuppurainen M.T., et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrinol Metab 84 (1999) 546-552
3. Bachmann G.A. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 180 (1999) S312-S316
4. Ancelin M.L., Scali J., and Ritchie K. Hormonal therapy and depression: are we overlooking an important therapeutic alternative?. J Psychosom Res 62 (2007) 473-485
5. Panay N., and Studd J.W. The psychotherapeutic effects of estrogens. Gynecol Endocrinol 12 (1998) 353-365
6. Lethaby A., Suckling J., Barlow D., Farquhar C.M., Jepson R.G., and Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev (2004) CD000402
7. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI trial. JAMA 1996;275:370-5.
8. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 (1999) 339-344
9. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
10. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
11. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., and Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11 (1996) 835-842
12. Heaney R.P., and Draper M.W. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82 (1997) 3425-3429
13. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., and Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177 (1997) 1458-1464
14. Mitlak B.H., and Cohen F.J. Selective estrogen receptor modulators: a look ahead. Drugs 57 (1999) 653-663
15. Cummings S.R., Eckert S., Krueger K.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 (1999) 2189-2197
16. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
17. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 118 Suppl 12B (2005) 74-78
18. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
19. Stovall D.W., Utian W.H., Gass M.L., et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 14 (2007) 510-517
20. Grady D., Ettinger B., Moscarelli E., et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104 (2004) 837-844
21. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 (2004) 1751-1761
22. Davis S.R., O'Neill S.M., Eden J., et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. Menopause 11 (2004) 167-175
23. Parsons A., Merritt D., Rosen A., Heath III H., Siddhanti S., and Plouffe Jr. L. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 101 (2003) 346-352